SCHEMBL1172007

SCHEMBL1172007

COc1cc(Nc2nccc(Nc3cccc4c3OC(F)(F)O4)n2)cc(OC)c1OC

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 13/20 0.57
SYK P43405 1/20 0.53
EGFR P00533 3/20 0.52
KDR P35968 3/20 0.52
INSR P06213 2/20 0.52
MET P08581 1/20 0.52
CDK2 P24941 1/20 0.52
TEK Q02763 1/20 0.52
EPHB4 P54760 1/20 0.52
AURKA O14965 2/20 0.50
PLK4 O00444 1/20 0.47
JAK2 O60674 1/20 0.47
MAP4K4 O95819 1/20 0.47
PAK4 O96013 1/20 0.47
NTRK1 P04629 1/20 0.47
LCK P06239 1/20 0.47
FYN P06241 1/20 0.47
CDK1 P06493 1/20 0.47
CSF1R P07333 1/20 0.47
LYN P07948 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1171685 0.82 EPHB4 (0.71) IGF1REGFRKDRINSRMET
SCHEMBL1116462 0.78 IGF1R (0.79) IGF1REGFRKDRINSRMET
SCHEMBL1172367 0.77 EPHB4 (0.63) IGF1RSYKKDREPHB4AURKA
SCHEMBL1172280 0.76 IGF1R (0.67) IGF1REGFRKDRINSRMET
SCHEMBL1172768 0.76 IGF1R (0.64) IGF1REGFRKDRINSRMET
SCHEMBL1172054 0.75 IGF1R (0.67) IGF1REGFRKDRINSRMET
SCHEMBL6981464 0.75 IGF1R (0.78) IGF1REGFRKDRINSRMET
SCHEMBL26506659 0.74 IGF1R (0.65) IGF1REGFRKDRINSRMET
SCHEMBL12865250 0.74 IGF1R (0.66) IGF1REGFRKDRINSRMET
SCHEMBL1171995 0.74 EPHB4 (0.59) IGF1REGFRKDRINSRMET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110046108-A1 PYRIMIDINE DERIVATIVES ASTRAZENECA AB (SE) 2011-02-24 US disclosed
EP-1981856-A2 PYRIMIDINE DERIVATIVES AstraZeneca AB (SE) 2008-10-22 EP disclosed
WO-2007085833-A2 PYRIMIDINE DERIVATIVES ASTRAZENECA AB (SE) 2007-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046108-A1 PYRIMIDINE DERIVATIVES EPHB4, EPHB1, EPHB3 IGF1R 1124/4885SYK 78/4885EGFR 25/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.